MindMed (MNMD) Q2 Net Loss Jumps 625%

Mind Medicine (MindMed) (NASDAQ:MNMD), a biopharmaceutical company developing psychedelic-inspired therapies for brain health disorders, reported its second quarter results on July 31, 2025. The company recorded a GAAP EPS loss of $0.50, wider than analyst expectations of $0.38. Operating costs rose sharply, and Net loss (GAAP) surpassed prior-year levels, reflecting significant clinical trial activity. Strong cash reserves provide a funding runway through 2027. The quarter demonstrated continued focus on advancing late-stage clinical programs, despite heightened losses and no short‑term revenue prospects.

Source: Analyst estimates for the quarter provided by FactSet.

MindMed focuses on developing treatments for mental health disorders using psychedelic compounds. Its research centers on product candidates for conditions such as generalized anxiety disorder (GAD), major depressive disorder (MDD), and autism spectrum disorder (ASD).

Continue reading

Source Fool.com